Get started
Work

Supplemental Figure S4 from Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody–Drug Conjugate for Treatment of CLDN18.2-Positive Cancers

Year: 2023
Type: supplementary-materials
Abstract: Selective efficacy of CLDN18.2-307-ADC compared to non-targeting control ADC in CLDN18.2 positive cell line xenografts.
DOI: 10.1158/1535-7163.24709954
Authors: Neil A. O'Brien, Martina S.J. McDermott, Jun Zhang, Ke Wei Gong, Ming Lu, Benjamin Hoffstrom, Tong Luo, Raul Ayala, Kevin Chau, Min Liang, Athena M. Madrid, Timothy R. Donahue, John A. Glaspy, Leonard Presta, Dennis J. Slamon
Language: English
Field: Medicine
Open Access status: gold
OpenAlex ID: W4389227292
Cites:
Cited by:
Related to: 10